drugset / Trial / NCT05981976

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

NCT05981976

Phase 1 Completed 174 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the relative absorption of abatacept in healthy participants following subcutaneous (SC) administration in which the drug substance is manufactured with the current or new process.

Timeline

Start
2023-08-18
Primary completion
2023-12-14
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified Subcutaneous

Indications

No indication recorded.